Mycoplasma pneumoniae-induced rash and mucositis in children –⁠ retrospective analysis

Czech version

Authors: Daniela Kapustová ¹; Tereza Neplechová ²; Denis Hrivnák ⁴; Zuzana Sroková ⁵; Karolína Vorčáková ^{- 1,2}; Otília Petrovičová ^1,3; Miloš Jeseňák ^1,3
Authors‘ workplace: Klinika detí a dorastu, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Univerzitná nemocnica Martin, Slovensko ¹; Dermatovenerologická klinika, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Univerzitná nemocnica Martin, Slovensko ²; Ústav klinickej imunológie a lekárskej genetiky, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Univerzitná nemocnica Martin, Slovensko ³; Klinika stomatológie a maxilofaciálnej chirurgie, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Univerzitná nemocnica Martin, Slovensko ⁴; Dermatovenerologická klinika, Slovenská zdravotnícka univerzita, Fakultná nemocnica s poliklinikou F. D. Roosevelta, Banská Bystrica, Slovensko ⁵
Published in: Čes-slov Pediat 2026; 81 (4): 214-219.
Category: Original Papers
doi: https://doi.org/10.55095/CSPediatrie2026/015

Overview

Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively recently described and rare condition that predominantly affects children and adolescence. Its true incidence remains unknown, which, together with the variable clinical presentation, significantly complicates diagnosis in clinical practice, not only for pediatricians but also for dermatologists. MIRM typical presents with extensive mucositis with prominent and occasionally vesiculobullous and/or targetoid, cutaneous erruptions. The clinical presentation is characterized by involvement of two or more organ systems, including the ocular, oral, and nasal mucosa, gastrointestinal tract, and genitourinary system, with mild skin involvement that may be completely absent. Currently, no standardized clinical management or treatment guidelines for MIRM exist. According to published data, the vast majority of patients are treated with targeted antibiotic therapy in combination with immunointerventional treatment, most commonly systemic corticosteroids and/or intravenous immunoglobulins, which appears to be effective. In this article, we present a retrospective analysis of a our cohort of patient in whom we diagnosed and treated MIRM, and provide an overview of the current state of knowledge regarding this condition.

Keywords:

Mycoplasma pneumoniae – mucositis – pediatric patient – MIRM – cutaneous lesions – rare skin disease

Sources

1. Kumar S. Mycoplasma pneumoniae: a significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. Indian J Med Res 2018; 147(1): 23–31.

2. Podraza Z, et al. The role of Mycoplasma pneumoniae in dermatological diseases. Dermatol Rev/Przegl Dermatol 2024; 111 : 39–46.

3. Meyer Sauteur PM, et al. Frequency and clinical presentation of mucocutaneous disease due to Mycoplasma pneumoniae infection in children with community-acquired pneumonia. JAMA Dermatol 2020; 156(2): 144–150.

4. Wang YS, et al. Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. World J Pediatr 2024; 20(9): 901–914.

5. Canavan TN, et al. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015; 72(2): 239–245.

6. Lofgren D, Lenkeit C. Mycoplasma pneumoniae-induced rash and mucositis: a systematic review of the literature. Spartan Med Res J 2021; 6(2): 25284.

7. Chen N, Li M. Case report and literature review: clinical characteristics of 10 children with Mycoplasma pneumoniae-induced rash and mucositis. Front Pediatr 2022; 10 : 823376.

8. Watkins LKF, et al. Epidemiology and molecular characteristics of Mycoplasma pneumoniae during an outbreak of M. pneumoniae-associated Stevens-Johnson syndrome. Pediatr Infect Dis J 2017; 36 : 564–571.

9. Mo X, et al. Case report: Mycoplasma pneumoniae-induced rash and mucositis in a child. Front Med 2025; 12 : 1607970.

10. Mayor-Ibarguren A, et al. Mucositis secondary to Chlamydia pneumoniae infection: expanding the Mycoplasma pneumoniae-induced rash and mucositis concept. Pediatr Dermatol 2017; 34 : 465–472.

11. Ryder CY, et al. Reactive infectious mucocutaneous eruption secondary to SARS-CoV-2. JAAD Case Rep 2021; 18 : 103–105.

12. Pan CX, Hussain SH. Recurrent reactive infectious mucocutaneous eruption: a retrospective cohort study. J Am Acad Dermatol 2023; 89(2): 361–364.

13. Lowell JA, et al. Rash from the past: a case of recurrent reactive infectious mucocutaneous eruption triggered by common coronavirus. JAAD Case Rep 2024; 47 : 26–29.

14. Ramien ML. Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol 2021; 46(3): 420–429.